Q4 EPS Estimate for DENTSPLY SIRONA Lowered by Analyst

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Research analysts at Leerink Partnrs dropped their Q4 2025 earnings estimates for shares of DENTSPLY SIRONA in a research report issued on Thursday, May 8th. Leerink Partnrs analyst M. Cherny now anticipates that the medical instruments supplier will earn $0.52 per share for the quarter, down from their previous estimate of $0.53. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Leerink Partnrs also issued estimates for DENTSPLY SIRONA’s FY2028 earnings at $2.59 EPS.

XRAY has been the subject of a number of other research reports. Barrington Research boosted their price objective on shares of DENTSPLY SIRONA from $20.00 to $21.00 and gave the company an “outperform” rating in a research report on Monday. StockNews.com raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Piper Sandler reduced their price target on DENTSPLY SIRONA from $20.00 to $16.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. Jefferies Financial Group cut DENTSPLY SIRONA from a “buy” rating to a “hold” rating and lowered their price objective for the company from $30.00 to $20.00 in a research report on Thursday, January 23rd. Finally, Robert W. Baird cut their price objective on DENTSPLY SIRONA from $22.00 to $20.00 and set a “neutral” rating for the company in a research note on Friday, February 28th. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, DENTSPLY SIRONA has a consensus rating of “Hold” and an average target price of $20.36.

DENTSPLY SIRONA Price Performance

NASDAQ XRAY opened at $16.60 on Monday. DENTSPLY SIRONA has a 52 week low of $12.16 and a 52 week high of $28.57. The firm has a market capitalization of $3.31 billion, a P/E ratio of -8.02, a PEG ratio of 1.80 and a beta of 0.92. The company has a quick ratio of 0.84, a current ratio of 1.25 and a debt-to-equity ratio of 0.72. The company has a 50-day moving average price of $14.38 and a 200-day moving average price of $17.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.29 by $0.14. The company had revenue of $879.00 million for the quarter, compared to analysts’ expectations of $854.75 million. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company posted $0.42 earnings per share.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of hedge funds have recently bought and sold shares of XRAY. Vanguard Group Inc. grew its stake in shares of DENTSPLY SIRONA by 2.8% in the 1st quarter. Vanguard Group Inc. now owns 20,740,589 shares of the medical instruments supplier’s stock worth $309,864,000 after buying an additional 557,329 shares in the last quarter. First Eagle Investment Management LLC grew its position in DENTSPLY SIRONA by 2.5% in the fourth quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier’s stock worth $275,218,000 after acquiring an additional 348,532 shares in the last quarter. Nuance Investments LLC increased its stake in DENTSPLY SIRONA by 25.0% during the fourth quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier’s stock worth $257,103,000 after acquiring an additional 2,708,097 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in DENTSPLY SIRONA by 18.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier’s stock valued at $238,186,000 after purchasing an additional 1,975,404 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its stake in shares of DENTSPLY SIRONA by 2.8% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 11,539,418 shares of the medical instruments supplier’s stock valued at $219,018,000 after purchasing an additional 314,343 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier bought 15,142 shares of the stock in a transaction dated Monday, March 3rd. The stock was purchased at an average cost of $16.51 per share, for a total transaction of $249,994.42. Following the transaction, the director now owns 81,971 shares of the company’s stock, valued at $1,353,341.21. The trade was a 22.66% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.50% of the stock is currently owned by company insiders.

DENTSPLY SIRONA Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date of this dividend was Friday, March 28th. DENTSPLY SIRONA’s payout ratio is presently -14.10%.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.